Xbiotech INC 10-Q quarterly reports

XBiotech Inc. filed its Q2 2026 Form 10-Q, detailing ongoing research and development efforts, continued net losses, and a cash position of $109.5 million.

XBiotech Inc. filed its Q1 2026 10-Q report, detailing a net loss of $5.5 million and a decrease in operating expenses, while maintaining a substantial cash reserve for ongoing research and development.

XBiotech Inc. reported a narrower net loss in Q3 2025, driven by decreased R&D expenses, while cash reserves declined to $147.4 million.

XBiotech Inc. reported a significantly reduced net loss for the second quarter of 2025, driven by lower operating expenses and a substantial foreign exchange gain, while maintaining a strong cash position.

XBiotech Inc. reports a net loss for Q1 2025, focusing on advancing its True Human pipeline and manufacturing system.

XBiotech Inc. reported a net loss of $5.0 million for the third quarter of 2024, while continuing to advance its pipeline of True Human antibody therapeutics.

XBiotech Inc. reported a net loss of $13.0 million for the second quarter of 2024, with increased research and development expenses.

XBiotech Inc. reported a net loss of $10 million for the first quarter of 2024, with increased research and development expenses and a new $10 million loan for facility construction.